# Bionano Targets Adjusted EBITDA Neutrality as a Profitability Goal By John Kim Canonical URL: https://www.tokenpost.com/news/business/54470 Published: 2026-11-11T21:10:04.000Z Updated: 2026-11-11T21:10:04.000Z Section: Business > The company also maintained its 2026 revenue guidance of $31 million to $33 million. Bionano Genomics, Inc. is targeting adjusted EBITDA neutrality, adding a profitability goal as it maintains 2026 revenue guidance of $31 million to $33 million. Adjusted EBITDA measures earnings before interest, taxes, depreciation and amortization, with specified adjustments. Neutrality means reaching break-even on that adjusted measure. Bionano’s third-quarter revenue rose 12%. Management warned that continued operations depended on raising additional funding amid expected losses and negative cash flows, as detailed in its [third-quarter results](). ## Links in this article - [third-quarter results](https://www.tokenpost.com/news/business/54399)